07:00 , Oct 8, 2007 |  BC Week In Review  |  Company News

Matritech, Sysmex Corp. deal

The partners ended a 2002 deal that granted Sysmex an exclusive, worldwide license to develop MZT's NMP179 cervical cancer technology for automated, non-slide-based laboratory instruments. The development of an automated cervical cell screening process using...
07:00 , May 17, 2004 |  BC Week In Review  |  Company News

Matritech, Sysmex Corp. other research news

The companies began testing 10,000 clinical samples using an approach that combines MZT's NMP179 biomarker and flow cytometry technology from Sysmex. Sysmex expects to bring the automated cervical cancer testing system to the market by...
08:00 , Nov 25, 2002 |  BC Week In Review  |  Company News

Matritech, Sysmex Corp. deal

The companies partnered to develop an automated Pap smear test. The test will use Sysmex's flow cytometry technology and NMPS's NMP179 protein biomarker to perform cell-by-cell analysis for cervical cancer. Under the deal, Sysmex will...
07:00 , Apr 2, 2001 |  BC Week In Review  |  Clinical News

NMP179 Test diagnostics/imaging data

NMPS said that in 384 cervical samples, NMP179 had 92.8% sensitivity in detecting high-grade squamous intraepithelial lesions (HSIL) compared to 85.7% sensitivity for Hybrid Capture II, a human papillomavirus (HPV)-based cervical cancer screening test from...
07:00 , Apr 10, 2000 |  BC Week In Review  |  Clinical News

NMP179 Test diagnostics/imaging data

Data from 259 patients with equivocal Pap smears in an 869-patient trial showed that NMP179 detected 92 percent of cases that were later diagnosed as high-grade squamous intraepithelial lesions via tissue biopsy or cytology. NMP179...
08:00 , Mar 6, 2000 |  BC Week In Review  |  Clinical News

NMP179 cervical cancer diagnostic regulatory update

NMPS received U.S. Patent No. 6,027,905 covering the use of its NMP179 test to identify and manage women with or at risk for cervical cancer. Matritech Inc. (NMPS), Newton, Mass.   Product: NMP179 cervical cancer...
08:00 , Dec 13, 1999 |  BC Week In Review  |  Clinical News

Matritech preclinical data

NMPS published in Acta Cytologica that in 261 cervical cytology specimens, NMP179 detected 97 percent of cases independently diagnosed as high-grade squamous intraepithelial lesions. Matritech Inc. (NMPS), Newton, Mass.   Product: NMP179 test   Indication:...
08:00 , Dec 21, 1998 |  BC Week In Review  |  Clinical News

Matritech preclinical data

Preclinical results showed the test to be 100 percent sensitive in detecting cancer in cervical tissue, with 7 of 7 specimens detected, as reported at the American Society for Cell Biology meeting in San Francisco....
08:00 , Nov 9, 1998 |  BC Week In Review  |  Clinical News

Matritech preclinical data

Data from a preclinical study showed that NMP179 was 92 percent sensitive and had a specificity of 73 percent in predicting the development of cervical dysplasia after a patient's Pap smear gave inconclusive results (atypical...
07:00 , May 26, 1998 |  BC Week In Review  |  Clinical News

Matritech preclinical data

NMPS said that in preclinical trials its antibody detected 100 percent of precancerous, high grade or advanced cervical dysplasia, as well as 76.7 percent of precancerous low grade or early stage dysplasia. Results were presented...